Peter Holleman

Peter Holleman

The complete DNA test allows for personalized treatment and so limits the chance of undesirable side effects.

Back to news

More news

GLOW: working toward more treatment options for glioblastoma

GLOW: working toward more treatment options for glioblastoma

23-05-2023

The outlook for patients with glioblastoma has been unfavorable for years, and treatment options remain limited. That is a reason …

In search of the optimal treatment strategy for glioblastoma 

In search of the optimal treatment strategy for glioblastoma 

30-05-2023

Patients with recurrent glioblastoma have an unfavorable outlook and few treatment options. The recently launched GLOW study should change this …

Accreditation renewed

Accreditation renewed

04-01-2021

In October 2020, we received formal notification of the renewal of our accreditation of ISO17025: 2005 into the 2017 version. We …

Would you like to be kept up to date with new developments?

Sign up for our newsletters

Want to know more about the complete DNA test?

Visit OncoAct.nl